Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Tubulis' Next-Gen ADC Shows Promise in Early Clinical Trial, Boosting Investor Confidence

Tubulis' Next-Gen ADC Shows Promise in Early Clinical Trial, Boosting Investor Confidence

In a significant development for the antibody-drug conjugate (ADC) field, German biotech company Tubulis has revealed promising early clinical data for its next-generation ADC, TUB-040. The results, presented at the European Society for Medical Oncology (ESMO) congress in Berlin, have justified recent investor interest and could potentially reshape the landscape of cancer treatment.

NoahAI News10/19/2025
GSK's ADC Pipeline Shows Promise with Latest Data from Hansoh Partnership

GSK's ADC Pipeline Shows Promise with Latest Data from Hansoh Partnership

GSK's antibody-drug conjugate (ADC) pipeline is gaining momentum, with encouraging data presented at the European Society for Medical Oncology (ESMO) congress in Berlin. The pharmaceutical giant's collaboration with Chinese company Hansoh is yielding positive results, particularly in the realm of oncology.

NoahAI News10/19/2025
Novartis' Pluvicto Shows Promise in Hormone-Sensitive Prostate Cancer, Plans FDA Submission

Novartis' Pluvicto Shows Promise in Hormone-Sensitive Prostate Cancer, Plans FDA Submission

Novartis has unveiled detailed data from its phase 3 PSMAddition trial, demonstrating that its radioligand therapy Pluvicto could significantly slow the progression of certain hormone-sensitive prostate cancers. The Swiss pharmaceutical giant plans to submit an application to the FDA by the end of the year, potentially doubling the number of patients eligible for the treatment.

NoahAI News10/19/2025
Roche's Giredestrant Shows Promise in Advanced Breast Cancer Treatment

Roche's Giredestrant Shows Promise in Advanced Breast Cancer Treatment

Roche, a leading pharmaceutical company, has unveiled promising results from a closely watched Phase 3 study of its experimental drug giredestrant for the treatment of advanced breast cancer. The data, presented at the European Society for Medical Oncology (ESMO) meeting in Berlin, demonstrates significant potential in delaying tumor progression and could position giredestrant as a strong competitor in the selective estrogen receptor degrader (SERD) market.

NoahAI News10/19/2025
Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit Therapeutics' novel bispecific antibody ivonescimab has demonstrated significant efficacy in first-line non-small cell lung cancer (NSCLC) treatment, according to results presented at the 2025 European Society for Medical Oncology (ESMO) congress in Berlin. The drug, which targets both PD-1 and VEGF, showed superior progression-free survival (PFS) compared to an established PD-1 inhibitor when combined with chemotherapy.

NoahAI News10/19/2025
FDA Unveils First Recipients of Commissioner's National Priority Voucher Program

FDA Unveils First Recipients of Commissioner's National Priority Voucher Program

The U.S. Food and Drug Administration (FDA) has announced the inaugural recipients of its Commissioner's National Priority Voucher program, a new initiative designed to accelerate the development and review of drugs that address critical national priorities. This program aims to incentivize pharmaceutical companies to focus on areas such as unmet medical needs, domestic manufacturing, and drug price reduction.

NoahAI News10/17/2025
Kite Pharma Inks $1.6B Deal with China's Pregene for In Vivo CAR-T Development

Kite Pharma Inks $1.6B Deal with China's Pregene for In Vivo CAR-T Development

Gilead Sciences' subsidiary Kite Pharma has announced a significant partnership with Chinese biotech Pregene Biopharma, marking another major investment in the burgeoning field of in vivo CAR-T therapy. The collaboration, valued at up to $1.64 billion, underscores the growing interest in next-generation cell therapies despite recent pullbacks from other pharmaceutical giants.

NoahAI News10/17/2025
Astellas Opts Out of Gene Therapy Collaboration with Taysha, Shifting Industry Landscape

Astellas Opts Out of Gene Therapy Collaboration with Taysha, Shifting Industry Landscape

Astellas Pharma has decided not to exercise its option to license Taysha Gene Therapies' lead asset, TSHA-102, marking a significant shift in the companies' collaboration and highlighting broader trends in the gene therapy sector. This development comes as the latest in a series of strategic moves by Astellas, reflecting the pharmaceutical giant's evolving approach to novel therapeutic modalities.

NoahAI News10/17/2025
Ōura Secures $900M in Funding, Valued at $11B as Wearable Health Tech Expands

Ōura Secures $900M in Funding, Valued at $11B as Wearable Health Tech Expands

Ōura, the smart ring manufacturer known for its health-tracking wearables, has successfully raised over $900 million in a new funding round, catapulting the company's valuation to approximately $11 billion. This significant investment comes as the lines between wellness devices and medical technology continue to blur, signaling a growing interest in consumer health monitoring tools.

NoahAI News10/17/2025
I-Mab Rebrands as NovaBridge Biosciences, Unveils New Global Strategy and Hong Kong IPO Plans

I-Mab Rebrands as NovaBridge Biosciences, Unveils New Global Strategy and Hong Kong IPO Plans

I-Mab Biopharma, a U.S.-listed biopharmaceutical company, has announced a comprehensive overhaul of its business strategy, including a name change to NovaBridge Biosciences, plans for a Hong Kong IPO, and the launch of a new subsidiary focused on ophthalmology. These developments mark a significant shift in the company's trajectory, less than two years after it had initially planned to divest its China operations and focus on the U.S. market.

NoahAI News10/17/2025
Pharmaceutical Industry Roundup: Major Deals, Funding, and Therapeutic Advances

Pharmaceutical Industry Roundup: Major Deals, Funding, and Therapeutic Advances

In a flurry of activity across the pharmaceutical landscape, companies are repositioning themselves, securing substantial funding, and forging new partnerships to advance innovative therapies. From strategic rebranding to breakthrough designations in gene therapy, the industry is witnessing significant developments that promise to shape the future of drug development and patient care.

NoahAI News10/17/2025
BMS Presents Promising Data for EGFRxHER3 Antibody-Drug Conjugate at ESMO 2025

BMS Presents Promising Data for EGFRxHER3 Antibody-Drug Conjugate at ESMO 2025

Bristol Myers Squibb (BMS) has unveiled encouraging results from an early-stage trial of its EGFRxHER3 antibody-drug conjugate (ADC), izalontamab brengitecan (iza-bren), at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. The data suggest that BMS may be positioned to maintain a competitive edge in the evolving ADC landscape.

NoahAI News10/17/2025
«1...363738...67»